VTYX Ventyx Bio: רווח למניה בשנים עשר החודשים האחרונים

Ventyx Biosciences has optimized its drug production through external contractors while maintaining full control over the cycles. On GURU.Markets, the annual net income per share trend is clearly visualized, and its current level is -1.49. The business foundation is built upon unique TYK2 inhibitors for combating inflammation, while the monetization of patents for lifelong therapy of chronic ailments ensures the company's long-term financial stability.

This indicator measures the real equity value of the business by calculating annual net income without accounting for capital dilution, allowing for an objective assessment of the company's internal efficiency. By analyzing the rolling 12-month earnings per share, an investor can see how the implementation of ESG principles and the optimization of laboratory energy costs at Ventyx Biosciences (VTYX) convert into fundamental growth in the asset's value.